Knight Therapeutics Raises 2026 Revenue and EBITDA Guidance
Knight reported nine-month revenue above $430 million and Adjusted EBITDA above $76 million. It raised 2026 revenue guidance to $560 million–$570 million from $540 million–$560 million and increased its Adjusted EBITDA outlook to approximately 17.5% of revenue from at least 15%.
Knight Therapeutics reported financial results for the third quarter ended September 30, 2026, highlighting record nine-month revenues exceeding $430 million and Adjusted EBITDA of over $76 million. The company raised its 2026 revenue guidance to a range of $560 million to $570 million, up from the previous $540 million to $560 million, and increased its Adjusted EBITDA outlook to approximately 17.5% of revenues from at least 15%. Management attributed the improved outlook to strong performance of promoted products and favorable currency impacts in Latin America.
Additionally, the company raised its peak annual revenue estimate for its pipeline and launched products to over $300 million. Knight also noted a favorable final decision from Brazil's Superior Chamber of Tax Appeals regarding goodwill tax reassessments and the completion of its Normal Course Issuer Bid (NCIB) program.